EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting

Lei Lv, Brenna L Brady, Lin Xie, Mico Guevarra, Alexander Turchin

Primary Care Diabetes · 2024-10 · 18 (5) · 511-517

DOI: 10.1016/j.pcd.2024.06.013 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Primary Care Diabetes, 2024-10. Verfasst von Lei Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, USA. Electronic address: lzlv@novonordisk.com. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Dipeptidyl-Peptidase IV Inhibitors, Medication Adherence. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk AS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesDipeptidyl-Peptidase IV InhibitorsMedication AdherenceHypoglycemic AgentsIncretinsGlucagon-Like Peptide-1 Receptor AgonistsHumansRetrospective StudiesMaleFemaleAdministration, OralMiddle AgedTreatment OutcomeAgedTime FactorsUnited StatesDatabases, FactualBiomarkersAdultDipeptidyl Peptidase 4SemaglutideGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

AdherenceDPP-4iOral semaglutidePersistenceType 2 diabetes

Substanzen

Glucagon-Like PeptidesDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsIncretinsBiomarkersDipeptidyl Peptidase 4Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideGLP1R protein, humanGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, USA. Electronic address: lzlv@novonordisk.com.
  • Merative, 100 Phoenix Dr Suite 200, Ann Arbor, MI 48108, USA.
  • Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, USA.
  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

Förderung

  • Novo Nordisk AS

Zitieren

APA

Lv, L., Brady, B. L., Xie, L., Guevarra, M., & Turchin, A. (2024). Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting. Primary Care Diabetes, 18(5), 511-517. https://doi.org/10.1016/j.pcd.2024.06.013

Vancouver

Lv L, Brady BL, Xie L, Guevarra M, Turchin A. Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting. Primary Care Diabetes. 2024;18(5):511-517. doi:10.1016/j.pcd.2024.06.013

BibTeX
@article{Lv2024,
  author = {Lv, Lei and Brady, Brenna L and Xie, Lin and Guevarra, Mico and Turchin, Alexander},
  title = {Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting},
  journal = {Primary Care Diabetes},
  year = {2024},
  volume = {18},
  number = {5},
  pages = {511--517},
  doi = {10.1016/j.pcd.2024.06.013}
}
Kostenlos starten →